Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.

doi:10.1158/1078-0432.CCR-23-3518

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 2 Dec 2024

Fléchon Aude, Morales-Barrera Rafael, Powles Thomas, Alva Ajjai, Özgüroğlu Mustafa, Csöszi Tibor, Loriot Yohann, Rodriguez-Vida Alejo, Géczi Lajos, Cheng Susanna Y, Fradet Yves, Oudard Stéphane, Vulsteke Christof, Gunduz Seyda, Mamtani Ronac, Yu Evan Y, Montesa Pino Alvaro, Anido Urbano, Sendur Mehmet A N, Gravis Gwenaelle, Révész János, Kostorov Vladimir, Huillard Olivier, Ma Junshui, Rajasagi Mohini, Vajdi Amir, Lunceford Jared, Cristescu Razvan, Imai Kentaro, Homet Moreno Blanca, Matsubara Nobuaki

Abstract excerpt

PURPOSE: The three-arm, phase III KEYNOTE-361 study did not meet its dual primary endpoints of progression-free survival (PFS) or overall survival (OS) with first-line pembrolizumab plus chemotherapy versus chemotherapy in advanced urothelial carcinoma. This prespecified exploratory analysis assessed the association of tumor mutational burden (TMB) and PD-L1 combined positive score (CPS) with clinical outcomes....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to Antineoplastic Combined Chemotherapy Protocols

Share to B7-H1 Antigen

Share to Carcinoma, Transitional Cell

Share to Exome Sequencing

Share to Urinary Bladder Neoplasms

Share to Urologic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 39475359
DOI: 10.1158/1078-0432.CCR-23-3518
PMCID: PMC11609623

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.PMID 39475359Read ↗

Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trialSemantic proximity Read ↗

Real-World Outcomes of Second-Line Pembrolizumab in Urothelial Carcinoma: A Multicenter Analysis from the Campania Oncological Network (ROC)Semantic proximity Read ↗

Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.Semantic proximity Read ↗

Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.Semantic proximity Read ↗

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.Semantic proximity Read ↗

Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.Semantic proximity Read ↗

Molecular determinants of response to PD-L1 blockade across tumor types.Semantic proximity Read ↗

Histological variant-specific significance of lymph node metastasis for the prognosis of metastatic urothelial carcinoma treated with pembrolizumab: A retrospective multicentric study (YUSHIMA study-04)Semantic proximity Read ↗

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.Semantic proximity Read ↗

Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma.Semantic proximity Read ↗

Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.